These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 21988213

  • 1. Improved glycemic control with weight loss and a low risk of hypoglycemia with insulin detemir: insights from the Italian cohort of the PREDICTIVE study after 6-month observation in type 2 diabetic subjects.
    Perriello G, Caputo S, De Pergola G, Di Carlo A, Grassi G, Lapolla A, Pata P, Solerte SB, Zaccardi F.
    Expert Opin Pharmacother; 2011 Nov; 12(16):2449-55. PubMed ID: 21988213
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [RESOLUTE Study in the Czech Republic: insulin glargine improves the compensation of type 2 diabetes in patients with unsatisfactory results of therapy with a combination of insulin detemir and oral antidiabetics. Results of the nonintervention RESOLUTE Project in the Czech Republic].
    Kvapil M.
    Vnitr Lek; 2013 Sep; 59(9):800-6. PubMed ID: 24073952
    [Abstract] [Full Text] [Related]

  • 4. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort.
    Dornhorst A, Lüddeke HJ, Sreenan S, Koenen C, Hansen JB, Tsur A, Landstedt-Hallin L.
    Int J Clin Pract; 2007 Mar; 61(3):523-8. PubMed ID: 17313628
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Once daily insulin detemir in patients with type 2 diabetes: results of German centers in a 6-month international observational study (SOLVE)].
    Liebl A, Wilhelm B, Kaiser M.
    MMW Fortschr Med; 2012 Dec 17; 154 Suppl 4():102-9. PubMed ID: 23326928
    [Abstract] [Full Text] [Related]

  • 9. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S, Koenen C, Bode B.
    Clin Ther; 2009 Oct 17; 31(10):2086-97. PubMed ID: 19922879
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Insulin Detemir in Combination with Oral Antidiabetic Drugs Improves Glycemic Control in Persons with Type 2 Diabetes in Near East Countries: Results from the Lebanese Subgroup.
    Echtay A, Andari E, Atallah P, Moufarrege R, Nemr R.
    Ethn Dis; 2017 Jan 19; 27(1):45-54. PubMed ID: 28115821
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain: 52-week data from the PREDICTIVE study in a cohort of French patients with type 1 or type 2 diabetes.
    Marre M, Pinget M, Gin H, Thivolet C, Hanaire H, Robert JJ, Fontaine P.
    Diabetes Metab; 2009 Dec 19; 35(6):469-75. PubMed ID: 19914118
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Clinical experience with insulin detemir: results from the Indonesian cohort of the international A₁chieve study.
    Soewondo P, Kshanti IA, Pramono RB, Langi YA, Dalem-Pemayun TG.
    Diabetes Res Clin Pract; 2013 Apr 19; 100 Suppl 1():S47-53. PubMed ID: 23647719
    [Abstract] [Full Text] [Related]

  • 18. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study.
    Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Lüddeke HJ.
    Diabetes Obes Metab; 2007 May 19; 9(3):418-27. PubMed ID: 17391170
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study.
    Dornhorst A, Lüddeke HJ, Honka M, Ackermann RW, Meriläinen M, Gallwitz B, Sreenan S, PREDICTIVE Study Group.
    Curr Med Res Opin; 2008 Feb 19; 24(2):369-76. PubMed ID: 18096110
    [Abstract] [Full Text] [Related]

  • 20. Observational 6-month open-label study of Japanese type 2 diabetes patients switching from NPH insulin to insulin detemir in basal-bolus regimen: 23rd article of the Japan Diabetes Clinical Data Management Study Group (JDDM23).
    Oishi M, Abe N, Yokoyama H, Kuribayashi N, Tomonaga O, Matoba K, Kobayashi M, Japan Diabetes Clinical Data Management Study Group.
    J Int Med Res; 2012 Feb 19; 40(2):787-97. PubMed ID: 22613444
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.